Peripheral Neuropathy Trial, Recruiting NCT07009717 Sponsor: University of Florida Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT07009717
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with Chemotherapy-Induced Peripheral Neuropathy (CIPN):

  • People aged 18 or older who can independently move their big toe up and down on their own
  • People who can read, understand, and complete questionnaires in English without help, and who have normal or corrected vision (such as wearing glasses or contact lenses)
  • People who are between 3 and 6 months into starting chemotherapy and have been formally diagnosed with CIPN through a nerve conduction study (a test that measures how well nerves send signals)

For the Healthy Control group (people without CIPN):

  • People aged 18 or older who can independently move their big toe up and down on their own
  • People who can read, understand, and complete questionnaires in English without help, and who have normal or corrected vision (such as wearing glasses or contact lenses)
  • People with no known health conditions that are associated with problems in movement, balance, or muscle strength, particularly in the legs and feet

Who may not be able to join:

For the CIPN group:

  • People who have other health conditions known to be linked to nerve damage or peripheral neuropathy, including but not limited to diabetes, arthritis, high blood pressure, thyroid disease, or heart disease
  • People who have toe shape or structural problems unrelated to CIPN, such as bunions, hammer toes, claw toes, webbed toes, or similar conditions (confirm with trial site for the full list)
  • People who report any weakness or reduced function in their foot, ankle, or big toe caused by a past illness or surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +1 (352) 273-9934

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 August 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Great Toe Strength; Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx); System Usability Scale (SUS) Questionnaire

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov